Connect Biopharma reports positive Phase 3 atopic dermatitis results

March 30, 2026 7:01 AM

Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced results from a 52-week Phase 3 study of rademikibart for moderate-to-severe atopic dermatitis ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found